非奈利酮的肾脏结局:来自FIGARO-DKD研究的分析
FIGARO-DKD研究纳入2型糖尿病合并1-4期慢性肾脏病患者,分析非奈利酮对肾脏结局的影响。结果显示非奈利酮对eGFR≥40%下降复合肾脏终点的事件发生率低于安慰剂,但组间差异未达统计学显著(HR=0.87,95%CI 0.76-1.01,P=0.069);对eGFR≥57%下降复合肾脏终点有更大治疗效应(HR=0.77,95%CI 0.60-0.99,P=0.041)。
要点
- 非奈利酮对eGFR≥40%下降复合肾脏终点的事件发生率低于安慰剂,但差异未达统计学显著(HR=0.87,95%CI 0.76-1.01,P=0.069)。
- 非奈利酮对eGFR≥57%下降复合肾脏终点显示更大治疗效应(HR=0.77,95%CI 0.60-0.99,P=0.041)。
- 在重度白蛋白尿患者中,非奈利酮对肾脏结局的效应幅度大于中度白蛋白尿患者。
核心结论
- 本分析提示非奈利酮可保护2型糖尿病合并早期或晚期慢性肾脏病患者的肾脏疾病进展并减少心血管事件。
研究设计与样本
- FIGARO-DKD(NCT02545049)纳入尿白蛋白与肌酐比值(UACR)30-<300 mg/g且估算肾小球滤过率(eGFR)25-90 mL/min/1.73 m2,或UACR 300-5000 mg/g且eGFR≥60 mL/min/1.73 m2的患者。
- 本分析进一步探讨FIGARO-DKD中的肾脏结局,评估两个复合肾脏终点、白蛋白尿变化及eGFR斜率,并按基线UACR评估肾脏与心血管结局。
主要发现
- 非奈利酮组eGFR≥40%下降复合肾脏终点的事件发生率低于安慰剂组,但组间差异未达统计学显著(HR=0.87,95%CI 0.76-1.01,P=0.069)。
- eGFR≥57%下降复合肾脏终点方面观察到更大的治疗效应(HR=0.77,95%CI 0.60-0.99,P=0.041),终末期肾病相对风险降低36%。
- 在重度白蛋白尿患者中,非奈利酮对肾脏结局的效应幅度大于中度白蛋白尿患者。
- 两个亚组中非奈利酮均可见UACR、eGFR斜率及心血管风险的改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1-4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients with advanced CKD. This analysis further explores kidney outcomes in FIGARO-DKD. METHODS: FIGARO-DKD (NCT02545049) included patients with urine albumin-to-creatinine ratio (UACR) 30-<300 mg/g and estimated glomerular filtration rate (eGFR) 25-90 mL/min/1.73 m2 or UACR 300-5000 mg/g and eGFR ≥60 mL/min/1.73 m2. Outcomes included two composite kidney endpoints, a composite of ≥40% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death, and a composite of ≥57% decrease in eGFR from baseline sustained over ≥4 weeks, kidney failure or renal death. Changes in albuminuria and eGFR slope were also analyzed. Kidney and CV outcomes were evaluated by baseline UACR. RESULTS: A lower incidence rate for the eGFR ≥40% kidney composite endpoint was observed with finerenone compared with placebo, but the between-group difference was not significant [hazard ratio (HR) = 0.87; 95% confidence interval (CI): 0.76-1.01; P = .069]. A greater treatment effect was observed on the eGFR ≥57% kidney composite endpoint (HR = 0.77; 95% CI: 0.60-0.99; P = 0.041) with a 36% relative risk reduction for end-stage kidney disease. A larger magnitude of effect on kidney outcomes was observed with finerenone versus placebo for patients with severely increased albuminuria than with moderately increased albuminuria. Improvements in UACR, eGFR slope and cardiovascular risk were evident in both subgroups with finerenone. CONCLUSIONS: The present analyses suggest that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early- or late-stage CKD.
引用
- Ruilope LM, Pitt B, Anker SD, et al. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023. PMID: 35451488. doi:10.1093/ndt/gfac157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。